Daniel H Johnson1, Charles Venuto, Marylyn D Ritchie, Gene D Morse, Eric S Daar, Paul J McLaren, David W Haas. 1. aDepartment of Medicine bDepartments of Pharmacology, Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee cThe Center for Human Experimental Therapeutics, University of Rochester Medical Center, Rochester dTranslational Pharmacology Research Core, University at Buffalo, SUNY, Buffalo, New York eDepartment of Biochemistry and Molecular Biology, The Pennsylvania State University, University Park, Pennsylvania fDepartment of Medicine, Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance, California, USA gDepartment of Life Sciences, The Swiss Institute of Technology hDepartment of Microbiology, University Hospital, University of Lausanne, Lausanne, Switzerland.
Abstract
BACKGROUND:Atazanavir-associated hyperbilirubinemia can cause premature discontinuation of atazanavir and avoidance of its initial prescription. We used genomewide genotyping and clinical data to characterize determinants of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202. METHODS:Plasma atazanavir pharmacokinetics and indirect bilirubin concentrations were characterized in HIV-1-infected patients randomized toatazanavir/ritonavir-containing regimens. A subset had genomewide genotype data available. RESULTS: Genomewide assay data were available from 542 participants, of whom 475 also had data on estimated atazanavir clearance and relevant covariates available. Peak bilirubin concentration and relevant covariates were available for 443 participants. By multivariate analysis, higher peak on-treatment bilirubin levels were found to be associated with the UGT1A1 rs887829 T allele (P=6.4×10(-12)), higher baseline hemoglobin levels (P=4.9×10(-13)), higher baseline bilirubin levels (P=6.7×10(-12)), and slower plasma atazanavir clearance (P=8.6×10(-11)). For peak bilirubin levels greater than 3.0 mg/dl, the positive predictive value of a baseline bilirubin level of 0.5 mg/dl or higher with hemoglobin concentrations of 14 g/dl or higher was 0.51, which increased to 0.85 with rs887829 TT homozygosity. For peak bilirubin levels of 3.0 mg/dl or lower, the positive predictive value of a baseline bilirubin level less than 0.5 mg/dl with a hemoglobin concentration less than 14 g/dl was 0.91, which increased to 0.96 with rs887829 CC homozygosity. No polymorphism predicted atazanavir pharmacokinetics at genomewide significance. CONCLUSION:Atazanavir-associated hyperbilirubinemia is best predicted by considering UGT1A1 genotype, baseline bilirubin level, and baseline hemoglobin level in combination. Use of ritonavir as a pharmacokinetic enhancer may have abrogated genetic associations with atazanavir pharmacokinetics.
RCT Entities:
BACKGROUND:Atazanavir-associated hyperbilirubinemia can cause premature discontinuation of atazanavir and avoidance of its initial prescription. We used genomewide genotyping and clinical data to characterize determinants of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202. METHODS: Plasma atazanavir pharmacokinetics and indirect bilirubin concentrations were characterized in HIV-1-infectedpatients randomized to atazanavir/ritonavir-containing regimens. A subset had genomewide genotype data available. RESULTS: Genomewide assay data were available from 542 participants, of whom 475 also had data on estimated atazanavir clearance and relevant covariates available. Peak bilirubin concentration and relevant covariates were available for 443 participants. By multivariate analysis, higher peak on-treatment bilirubin levels were found to be associated with the UGT1A1rs887829 T allele (P=6.4×10(-12)), higher baseline hemoglobin levels (P=4.9×10(-13)), higher baseline bilirubin levels (P=6.7×10(-12)), and slower plasma atazanavir clearance (P=8.6×10(-11)). For peak bilirubin levels greater than 3.0 mg/dl, the positive predictive value of a baseline bilirubin level of 0.5 mg/dl or higher with hemoglobin concentrations of 14 g/dl or higher was 0.51, which increased to 0.85 with rs887829 TT homozygosity. For peak bilirubin levels of 3.0 mg/dl or lower, the positive predictive value of a baseline bilirubin level less than 0.5 mg/dl with a hemoglobin concentration less than 14 g/dl was 0.91, which increased to 0.96 with rs887829 CC homozygosity. No polymorphism predicted atazanavir pharmacokinetics at genomewide significance. CONCLUSION:Atazanavir-associated hyperbilirubinemia is best predicted by considering UGT1A1 genotype, baseline bilirubin level, and baseline hemoglobin level in combination. Use of ritonavir as a pharmacokinetic enhancer may have abrogated genetic associations with atazanavir pharmacokinetics.
Authors: M R Nelson; S-A Bacanu; M Mosteller; L Li; C E Bowman; A D Roses; E H Lai; M G Ehm Journal: Pharmacogenomics J Date: 2008-02-26 Impact factor: 3.550
Authors: Andrew D Johnson; Maryam Kavousi; Albert V Smith; Ming-Huei Chen; Abbas Dehghan; Thor Aspelund; Jing-Ping Lin; Cornelia M van Duijn; Tamara B Harris; L Adrienne Cupples; Andre G Uitterlinden; Lenore Launer; Albert Hofman; Fernando Rivadeneira; Bruno Stricker; Qiong Yang; Christopher J O'Donnell; Vilmundur Gudnason; Jacqueline C Witteman Journal: Hum Mol Genet Date: 2009-05-04 Impact factor: 6.150
Authors: R M M Cleijsen; M E van de Ende; F P Kroon; F Verduyn Lunel; P P Koopmans; L Gras; F de Wolf; D M Burger Journal: J Antimicrob Chemother Date: 2007-08-17 Impact factor: 5.790
Authors: C Torti; G Lapadula; A Antinori; T Quirino; R Maserati; F Castelnuovo; F Maggiolo; A De Luca; G Paraninfo; F Antonucci; G Migliorino; A Lazzarin; G Di Perri; G Rizzardini; R Esposito; G Carosi Journal: Infection Date: 2009-05-26 Impact factor: 3.553
Authors: Marco Siccardi; Antonio D'Avolio; Lorena Baietto; Sara Gibbons; Mauro Sciandra; Daniela Colucci; Stefano Bonora; Saye Khoo; David J Back; Giovanni Di Perri; Andrew Owen Journal: Clin Infect Dis Date: 2008-11-01 Impact factor: 9.079
Authors: E Link; S Parish; J Armitage; L Bowman; S Heath; F Matsuda; I Gut; M Lathrop; R Collins Journal: N Engl J Med Date: 2008-07-23 Impact factor: 91.245
Authors: Serena Sanna; Fabio Busonero; Andrea Maschio; Patrick F McArdle; Gianluca Usala; Mariano Dei; Sandra Lai; Antonella Mulas; Maria Grazia Piras; Lucia Perseu; Marco Masala; Mara Marongiu; Laura Crisponi; Silvia Naitza; Renzo Galanello; Gonçalo R Abecasis; Alan R Shuldiner; David Schlessinger; Antonio Cao; Manuela Uda Journal: Hum Mol Genet Date: 2009-05-06 Impact factor: 6.150
Authors: Valentine Wanga; Charles Venuto; Gene D Morse; Edward P Acosta; Eric S Daar; David W Haas; Chun Li; Bryan E Shepherd Journal: Pharmacogenet Genomics Date: 2015-09 Impact factor: 2.089
Authors: David S Lehmann; Heather J Ribaudo; Eric S Daar; Roy M Gulick; Richard H Haubrich; Gregory K Robbins; Paul I W de Bakker; David W Haas; Paul J McLaren Journal: Pharmacogenet Genomics Date: 2015-02 Impact factor: 2.089
Authors: R S Gammal; M H Court; C E Haidar; O F Iwuchukwu; A H Gaur; M Alvarellos; C Guillemette; J L Lennox; M Whirl-Carrillo; S S Brummel; M J Ratain; T E Klein; B R Schackman; K E Caudle; D W Haas Journal: Clin Pharmacol Ther Date: 2015-11-09 Impact factor: 6.875
Authors: Kristine M Erlandson; Yuki Bradford; David C Samuels; Todd T Brown; Jing Sun; Kunling Wu; Katherine Tassiopoulos; Marylyn D Ritchie; David W Haas; Todd Hulgan Journal: AIDS Res Hum Retroviruses Date: 2020-01-14 Impact factor: 2.205